Protease-activated receptor-1 antagonist F 16618 reduces arterial restenosis by down-regulation of tumor necrosis factor α and matrix metalloproteinase 7 expression, migration, and proliferation of vascular smooth muscle cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 336, Issue 3, 2011, Pages 643-651

  Chieng Yane, Pauline ^b   Bocquet, Arnaud ^a   Létienne, Robert ^a   Bourbon, Thierry ^a   Sablayrolles, Sylvie ^a   Perez, Michel ^a   Hatem, Stéphane Nicolas ^b   Lompré, Anne Marie ^b   Le Grand, Bruno ^a   David Dufilho, Monique ^b  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 [5 OXO 5 (4 PYRIDIN 2 YLPIPERAZIN 1 YL)PENTA 1,3 DIENYL]BENZONITRILE; ANTICOAGULANT AGENT; F 16618; INTERLEUKIN 6; MATRILYSIN; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; CAROTID ARTERY OBSTRUCTION; CELL DIFFERENTIATION; CELL GROWTH; CELL LOSS; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; HEART PROTECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANIMALS; CAROTID STENOSIS; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CORONARY RESTENOSIS; DOWN-REGULATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MALE; MATRIX METALLOPROTEINASE 7; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PIPERAZINES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, PAR-1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79951963196     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.175182     Document Type: Article

References (39)

1. Andrade-Gordon P, Derian CK, Maryanoff BE, Zhang HC, Addo MF, Cheung W, Damiano BP, D'Andrea MR, Darrow AL, de Garavilla L, et al. (2001) Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats. J Pharmacol Exp Ther 298:34-42. (Pubitemid 32574507)
2. Bocquet A, Létienne R, Sablayrolles S, De Vries L, Perez M, and Le Grand B (2009) Effects of a new PAR1 antagonist, F 16618, on smooth muscle cell contraction. Eur J Pharmacol 611:60-63.
3. Borensztajn K, Peppelenbosch MP, and Spek CA (2008) Factor Xa: at the crossroads between coagulation and signaling in physiology and disease. Trends Mol Med 14:429-440.
4. Brandes RP, Viedt C, Nguyen K, Beer S, Kreuzer J, Busse R, and Görlach A (2001) Thrombin-induced MCP-1 expression involves activation of the p22phoxcontaining NADPH oxidase in human vascular smooth muscle cells. Thromb Haemost 85:1104-1110. (Pubitemid 32573767)
5. Brasier AR (2010) The nuclear factor-κB-interleukin-6 signalling pathway mediating vascular inflammation. Cardiovasc Res 86:211-218.
6. Burchenal JE, Marks DS, Tift Mann J, Schweiger MJ, Rothman MT, Ganz P, Adelman B, and Bittl JA (1998) Effect of direct thrombin inhibition with Bivalirudin (Hirulog) on restenosis after coronary angioplasty. Am J Cardiol 82:511-515. (Pubitemid 28389952)
7. Camerer E, Huang W, and Coughlin SR (2000) Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci USA 97:5255-5260. (Pubitemid 30313705)
8. Cipollone F, Marini M, Fazia M, Pini B, Iezzi A, Reale M, Paloscia L, Materazzo G, D'Annunzio E, Conti P, et al. (2001) Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vasc Biol 21:327-334. (Pubitemid 32199112)
9. Coughlin SR (2000) Thrombin signalling and protease-activated receptors. Nature 407:258-264.
10. Déry O, Corvera CU, Steinhoff M, and Bunnett NW (1998) Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. Am J Physiol 274: C1429-C1452.
11. Douglas JS Jr (2007) Pharmacologic approaches to restenosis prevention. Am J Cardiol 100:10K-16K.
12. Dridi SM, Foucault Bertaud A, Igondjo Tchen S, Senni K, Ejeil AL, Pellat B, Lyonnet S, Bonnet D, Charpiot P, and Godeau G (2005) Vascular wall remodeling in patients with supravalvular aortic stenosis and Williams Beuren syndrome. J Vasc Res 42:190-201. (Pubitemid 40981126)
13. Fukunaga R, Hirano K, Hirano M, Niiro N, Nishimura J, Maehara Y, and Kanaide H (2006) Upregulation of proteinase-activated receptors and hypercontractile responses precede development of arterial lesions after balloon injury. Am J Physiol Heart Circ Physiol 291:H2388-H2395.
14. Galis ZS and Khatri JJ (2002) Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90:251-262. (Pubitemid 34633925)
15. Hirano K (2007) The roles of proteinase-activated receptors in the vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 27:27-36.
16. Hollenberg MD and Compton SJ (2002) International Union of Pharmacology. XXVIII. Proteinase-activated receptors. Pharmacol Rev 54:203-217.
17. Inoue T and Node K (2009) Molecular basis of restenosis and novel issues of drugeluting stents. Circ J 73:615-621.
18. Jones GT, Tarr GP, Phillips LV, Wilkins GT, van Rij AM, and Williams MJ (2009) Active matrix metalloproteinases 3 and 9 are independently associated with coronary artery in-stent restenosis. Atherosclerosis 207:603-607.
19. Kai Y, Hirano K, Maeda Y, Nishimura J, Sasaki T, and Kanaide H (2007) Prevention of the hypercontractile response to thrombin by proteinase-activated receptor-1 antagonist in subarachnoid hemorrhage. Stroke 38:3259-3265. (Pubitemid 350175746)
20. Kalmes A, Daum G, and Clowes AW (2001) EGFR transactivation in the regulation of SMC function. Ann NY Acad Sci 947:42-54; discussion 54-55.
21. Khachigian LM (2006) Early growth response-1 in cardiovascular pathobiology. Circ Res 98:186-191.
22. Kinlough-Rathbone RL, Rand ML, and Packham MA (1993) Rabbit and rat platelets do not respond to thrombin receptor peptides that activate human platelets. Blood 82:103-106. (Pubitemid 23188752)
23. Lee HB and Blaufox MD (1985) Blood volume in the rat. J Nucl Med 26:72-76. (Pubitemid 15161428)
24. Létienne R, Leparq-Panissié A, Bocquet A, Calmettes Y, Culié C, and Le Grand B (2010a) PAR1 antagonist mediated antithrombotic activity in extracorporeal arterio-venous shunt in the rat. Thromb Res 125:257-261.
25. Létienne R, Leparq-Panissié A, Calmettes Y, Nadal-Wollbold F, Perez M, and Le Grand B (2010b) Antithrombotic activity of F 16618, a new PAR1 antagonist evaluated in extracorporeal arterio-venous shunt in the rat. Biochem Pharmacol 79:1616-1621.
26. Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, and Plevin R (2001) Proteinaseactivated receptors. Pharmacol Rev 53:245-282.
27. Marmur JD, Merlini PA, Sharma SK, Khaghan N, Torre SR, Israel DH, Ardissino D, and Ambrose JA (1994) Thrombin generation in human coronary arteries after percutaneous transluminal balloon angioplasty. J Am Coll Cardiol 24:1484-1491. (Pubitemid 24344244)
28. Minami T, Sugiyama A, Wu SQ, Abid R, Kodama T, and Aird WC (2004) Thrombin and phenotypic modulation of the endothelium. Arterioscler Thromb Vasc Biol 24:41-53. (Pubitemid 38082410)
29. Monraats PS, Pires NM, Schepers A, Agema WR, Boesten LS, de Vries MR, Zwinderman AH, de Maat MP, Doevendans PA, de Winter RJ, et al. (2005) Tumor necrosis factor-α plays an important role in restenosis development. Faseb J 19:1998-2004. (Pubitemid 41759745)
30. Muto A, Fitzgerald TN, Pimiento JM, Maloney SP, Teso D, Paszkowiak JJ, Westvik TS, Kudo FA, Nishibe T, and Dardik A (2007) Smooth muscle cell signal transduction: implications of vascular biology for vascular surgeons. J Vasc Surg 45: A15-A24.
31. Perez M, Lamothe M, Maraval C, Mirabel E, Loubat C, Planty B, Horn C, Michaux J, Marrot S, Letienne R, et al. (2009) Discovery of novel protease activated receptors 1 antagonists with potent antithrombotic activity in vivo. J Med Chem 52:5826-5836.
32. Schrör K, Bretschneider E, Fischer K, Fischer JW, Pape R, Rauch BH, Rosenkranz AC, and Weber AA (2010) Thrombin receptors in vascular smooth muscle cells - function and regulation by vasodilatory prostaglandins. Thromb Haemost 103: 884-890.
33. Siller-Matula JM, Krumphuber J, and Jilma B (2010) Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. Br J Pharmacol 159:502-517.
34. Steinberg SF (2005) The cardiovascular actions of protease-activated receptors. Mol Pharmacol 67:2-11.
35. Vu TK, Hung DT, Wheaton VI, and Coughlin SR (1991) Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64:1057-1068. (Pubitemid 121001193)
36. Welt FG and Rogers C (2002) Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 22:1769-1776. (Pubitemid 35315761)
37. Wessely R (2010) New drug-eluting stent concepts. Nat Rev Cardiol 7:194-203.
38. Woessner JF Jr (1995) Matrilysin. Methods Enzymol 248:485-495.
39. Zargham R (2008) Preventing restenosis after angioplasty: a multistage approach. Clin Sci 114:257-264.